@Article{wjcea1211,
AUTHOR = {Gorani, Manas},
TITLE = {Pharmaceutical Supply Chain Distribution: Mitigating the Risk of Counterfeit Drugs},
JOURNAL = {World Journal of Civil Engineering and Architecture},
VOLUME = {3},
YEAR = {2023},
NUMBER = {1},
PAGES = {1-6},
URL = {https://www.scipublications.com/journal/index.php/OJMS/article/view/1211},
ISSN = {2836-0044},
DOI = {10.31586/ojms.2023.1211},
ABSTRACT = {The global pharmaceutical supply chain plays a crucial role in ensuring the timely and safe delivery of medicines to patients worldwide. However, the increasing presence of counterfeit drugs within this supply chain poses a significant and growing risk to public health, patient safety, and the integrity of the pharmaceutical industry. Counterfeit drugs—medications that are fraudulently manufactured, mislabeled, or contain incorrect or harmful ingredients—are a major concern as they can lead to ineffective treatments, adverse health effects, and even death. Despite stringent regulatory frameworks and advanced technological solutions, counterfeit drugs continue to infiltrate legitimate supply chains due to factors such as the complexity of the distribution system, global trade practices, and inadequate enforcement in certain regions. This manuscript explores the primary causes behind the proliferation of counterfeit drugs in pharmaceutical distribution, the associated risks, and the multifaceted approaches required to address this growing threat. It discusses the importance of regulatory measures, including international cooperation and stronger compliance frameworks, as well as the role of emerging technologies like serialization, blockchain, and RFID in ensuring traceability and product authenticity. By focusing on the integration of these technologies, the paper also highlights the potential of innovative solutions to enhance transparency, reduce vulnerabilities, and protect the integrity of pharmaceutical supply chains. Additionally, it emphasizes the importance of public awareness campaigns and collaboration between key stakeholders, including pharmaceutical manufacturers, distributors, regulators, and healthcare providers, in creating a more secure and trustworthy pharmaceutical distribution ecosystem. Through a comprehensive exploration of these strategies, this manuscript aims to provide a roadmap for mitigating the risks posed by counterfeit drugs and ensuring the safety and efficacy of medicines for consumers worldwide.},
}

%0 Journal Article
%A Gorani, Manas
%D 2023
%J World Journal of Civil Engineering and Architecture

%@ 2836-0044
%V 3
%N 1
%P 1-6

%T Pharmaceutical Supply Chain Distribution: Mitigating the Risk of Counterfeit Drugs
%M doi:10.31586/ojms.2023.1211
%U https://www.scipublications.com/journal/index.php/OJMS/article/view/1211

TY  - JOUR
AU  - Gorani, Manas
TI  - Pharmaceutical Supply Chain Distribution: Mitigating the Risk of Counterfeit Drugs
T2  - World Journal of Civil Engineering and Architecture
PY  - 2023
VL  - 3
IS  - 1
SN  - 2836-0044
SP  - 1
EP  - 6
UR  - https://www.scipublications.com/journal/index.php/OJMS/article/view/1211
AB  - The global pharmaceutical supply chain plays a crucial role in ensuring the timely and safe delivery of medicines to patients worldwide. However, the increasing presence of counterfeit drugs within this supply chain poses a significant and growing risk to public health, patient safety, and the integrity of the pharmaceutical industry. Counterfeit drugs—medications that are fraudulently manufactured, mislabeled, or contain incorrect or harmful ingredients—are a major concern as they can lead to ineffective treatments, adverse health effects, and even death. Despite stringent regulatory frameworks and advanced technological solutions, counterfeit drugs continue to infiltrate legitimate supply chains due to factors such as the complexity of the distribution system, global trade practices, and inadequate enforcement in certain regions. This manuscript explores the primary causes behind the proliferation of counterfeit drugs in pharmaceutical distribution, the associated risks, and the multifaceted approaches required to address this growing threat. It discusses the importance of regulatory measures, including international cooperation and stronger compliance frameworks, as well as the role of emerging technologies like serialization, blockchain, and RFID in ensuring traceability and product authenticity. By focusing on the integration of these technologies, the paper also highlights the potential of innovative solutions to enhance transparency, reduce vulnerabilities, and protect the integrity of pharmaceutical supply chains. Additionally, it emphasizes the importance of public awareness campaigns and collaboration between key stakeholders, including pharmaceutical manufacturers, distributors, regulators, and healthcare providers, in creating a more secure and trustworthy pharmaceutical distribution ecosystem. Through a comprehensive exploration of these strategies, this manuscript aims to provide a roadmap for mitigating the risks posed by counterfeit drugs and ensuring the safety and efficacy of medicines for consumers worldwide.
DO  - Pharmaceutical Supply Chain Distribution: Mitigating the Risk of Counterfeit Drugs
TI  - 10.31586/ojms.2023.1211
ER  -